trial

The Effect of Paliperidone Palmitate in Schizophrenia

NCTId NCT01860781
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 30 (actual)
Sponsored by Seoul National University Hospital
Primary completion 2015-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
30 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2011-08
Primary completion
2015-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Paliperidone

Sponsors

Seoul National University HospitalLead Sponsor

Investigators

1
Yong Min Ahn, MD, PhDPrincipal Investigator

Sites

1 total
Seoul, South Korea

Facts & assertions

4 sourced
Enrollment
30
Phase
PHASE4
Primary Completion Date
2015-12
Status
COMPLETED
relationships
The graph out of here
drug
Paliperidone
drug
lead_sponsor
Seoul National University Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Yong Min Ahn, MD, PhD
person